320590-29-2

Usage

Uses

Used in Pharmaceutical Industry:
3-N-CBZ-AMINO-CYCLOHEXANONE is used as a key intermediate in the synthesis of various drugs and medications, contributing to the development of new therapeutic agents.
Used in Organic Synthesis:
3-N-CBZ-AMINO-CYCLOHEXANONE is used as a building block for creating more complex organic molecules, facilitating the advancement of organic chemistry.
Used in Research and Development:
3-N-CBZ-AMINO-CYCLOHEXANONE is utilized in research for its potential therapeutic properties, such as anticonvulsant and anti-inflammatory effects, indicating its importance in the discovery of novel treatments for various conditions.

Upstream product

• 501-53-1 benzyl chloroformate 
• 149520-74-1 1-aminocyclohexan-3-one 
• 930-68-7 cyclohexenone 
• 885280-38-6 (3-oxo-cyclohexyl)-carbamic acid tert-butyl ester 
• 750649-39-9 ((1R,3S)-3-hydroxycyclohexyl)carbamic acid benzyl ester 
• 621-84-1 O-benzyl carbamate 
• 1110772-04-7 (1S,3R)-3-aminocyclohexan-1-ol 
• 6850-39-1 3-aminocyclohexanol 
• 955406-36-7 (3-hydroxycyclohexyl)carbamic acid benzyl ester 

Downstream Products

• 1424336-61-7 C₂₀H₂₀ClN₃O₂ 
• 1424336-60-6 C₂₀H₂₀ClN₃O₂ 
• 921602-76-8 benzyl N-(3,3-difluorocyclohexyl)carbamate 
• 750649-39-9 cis-benzyl (3-hydroxycyclohexyl)carbamate 
• 750649-39-9 trans-benzyl (3-hydroxycyclohexyl)carbamate 

Relevant academic research and scientific papers

Transition Metal Salts-Catalyzed Aza-Michael Reactions of Enones with Carbamates

(Matrix Presented) Several transition metal salts were found to catalyze aza-Michael reactions of enones with carbamates efficiently. The catalytic activity was strongly dependent on the nature of the metal salts. While conventional Lewis acids such as BF

An efficient and inexpensive catalyst system for the aza-Michael reactions of enones with carbamates

A new strategy which uses very cheap FeCl3 as an effective catalyst in the presence of Me3SiCl has been developed for the conjugate addition of enones and chalcone with unactivated weakly nucleophilic carbamates.

Highly efficient phosphine-catalyzed aza-Michael reactions of α,β-unsaturated compounds with carbamates in the presence of TMSCl

Aza-Michael reactions of enones with carbamates took place efficiently in the presence of a catalytic amount of phosphine and TMSCl to afford the total products in high yields. The new catalytic system was also efficient in the aza-Michael reaction of chalcone, which was difficult to react with carbamates by transition metal salts catalysts.

Derailing the Wacker oxidation: Development of a palladium-catalyzed amidation reaction

(equation presented) 96 % isolated yield A conceptually new palladium-catalyzed amidation reaction is described for the synthesis of β-amido ketones based on derailing the Wacker oxidation of enones. This reaction generates a new carbon-nitrogen bond via a palladium-catalyzed conjugate addition of a carbamate nucleophile to an enone. The regiocontrol, mild and neutral conditions, lack of preactivation of the nucleophile, and lack of reoxidation system for the catalyst are attractive features of this transformation.

Discovery of the c-Jun N-Terminal Kinase Inhibitor CC-90001

As a result of emerging biological data suggesting that within the c-Jun N-terminal kinase (JNK) family, JNK1 and not JNK2 or JNK3 may be primarily responsible for fibrosis pathology, we sought to identify JNK inhibitors with an increased JNK1 bias relative to our previous clinical compound tanzisertib (CC-930). This manuscript reports the synthesis and structure-activity relationship (SAR) studies for a novel series of JNK inhibitors demonstrating an increased JNK1 bias. SAR optimization on a series of 2,4-dialkylamino-pyrimidine-5-carboxamides resulted in the identification of compounds possessing low nanomolar JNK inhibitory potency, overall kinome selectivity, and the ability to inhibit cellular phosphorylation of the direct JNK substrate c-Jun. Optimization of physicochemical properties in this series resulted in compounds that demonstrated excellent systemic exposure following oral dosing, enabling in vivo efficacy studies and the selection of a candidate for clinical development, CC-90001, which is currently in clinical trials (Phase II) in patients with idiopathic pulmonary fibrosis (NCT03142191).

NLRP3 INFLAMMASOME INHIBITORS

The present invention relates to novel thienopyrrolotriazinacetamide compounds of Formula (I): wherein R1, R2 and R3 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The inventio

THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE

Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.

Divergent Stereoselectivity in Phosphothreonine (pThr)-Catalyzed Reductive Aminations of 3-Amidocyclohexanones

Phosphothreonine (pThr)-embedded peptide catalysts are found to mediate the reductive amination of 3-amidocyclohexanones with divergent selectivity. The choice of peptide sequence can be used to alter the diastereoselectivity to favor either the cis-product or trans-product, which are obtained in up to 93:7 er. NMR studies and DFT calculations are reported and indicate that both pathways rely on secondary interactions between substrate and catalyst to achieve selectivity. Furthermore, catalysts appear to accomplish a parallel kinetic resolution of the substrates. The facility for phosphopeptides to tune reactivity and access multiple products in reductive aminations may translate to the diversification of complex substrates, such as natural products, at numerous reactive sites.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Catalyst control over regio- and enantioselectivity in baeyer-villiger oxidations of functionalized ketones

We report a peptide-based catalyst that can strongly influence the regio- and enantioselectivity of the Baeyer-Villiger (BV) oxidation of cyclic ketones bearing amide, urea, or sulfonamide functional groups. Both types of selectivity are thought to arise from a catalyst-substrate hydrogen-bonding interaction. Furthermore, in selected cases, the reactions exhibit the hallmarks of parallel kinetic resolution. The capacity to use catalysis to select between BV products during an asymmetric process may have broad utility for both the synthesis and diversification of complex molecules, including natural products.